Evidence map›Paper›PMID 37119314›Full record

Trial reportAnnals of hematology2023

Switching from imatinib to nilotinib plus pegylated interferon-α2b in chronic phase CML failing to achieve deep molecular response: clinical and immunological effects.

Inge G P Geelen, Stein-Erik Gullaksen, Mette M Ilander, Ulla Olssen-Strömberg, Satu Mustjoki, Johan Richter, Nicole M A Blijlevens, Willem M Smit, Bjorn T Gjertsen, Tobias Gedde-Dahl and 5 more

Open access · greenAbstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in Annals of hematology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 11 institutions in 4 countries.

Inge G P GeelenDepartment of Internal Medicine / Hematology, Albert Schweitzer Hospital, Dordrecht, The Netherlands. i.geelen@erasmusmc.nl.ORCID http://orcid.org/0000-0001-9470-476X
Stein-Erik GullaksenCentre of Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway.
Mette M IlanderHematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital Comprehensive Cancer center, Helsinki, Finland.
Ulla Olssen-StrömbergDepartment of Hematology, Uppsala University Hospital, Uppsala, Sweden.
Satu MustjokiHematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital Comprehensive Cancer center, Helsinki, Finland.
Johan RichterDepartment of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden.
Nicole M A BlijlevensDepartment of Hematology, Radboud UMC, Nijmegen, The Netherlands.
Willem M SmitDepartment of Hematology, Medical Spectrum Twente, Enschede, The Netherlands.
Bjorn T GjertsenCentre of Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway.
Tobias Gedde-DahlDepartment of Hematology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
Berit MarkevärnDepartment of Hematology, Umeå University Hospital, Umeå, Sweden.
Malika M A KoppesDepartment of Hematology, Amsterdam University Medical Centers, location VUmc, Amsterdam, The Netherlands.
Peter E WesterweelDepartment of Internal Medicine / Hematology, Albert Schweitzer Hospital, Dordrecht, The Netherlands.
Henrik Hjorth-HansenDepartment of Hematology, St Olavs Hospital, Trondheim, Norway.
Jeroen J W M JanssenDepartment of Hematology, Amsterdam University Medical Centers, location VUmc, Amsterdam, The Netherlands.
Albert Schweitzer Ziekenhuis · NLAmsterdam University Medical Centers · NLUniversity of Bergen · NOUniversity of Helsinki · FIMedisch Spectrum Twente · NLNorwegian University of Science and Technology · NOOslo University Hospital · NORadboud University Nijmegen · NLSkåne University Hospital · SEUmeå University · SEUppsala University Hospital · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In order to improve molecular response for a discontinuation attempt in chronic myeloid leukemia (CML) patients in chronic phase, who had not achieved at least a molecular response <0.01% BCR-ABL1

Indexed as

Leukemia, Myeloid, Chronic-PhaseProtein Kinase InhibitorsFusion Proteins, bcr-ablHumansImatinib MesylateInterferon-alphaInterferon alpha-2Polyethylene GlycolsPyrimidinesTreatment OutcomeFusion Proteins, bcr-ablImatinib MesylateInterferon-alphaInterferon alpha-2Interferon-alpha2bPolyethylene GlycolsProtein Kinase InhibitorsPyrimidinesChronic myeloid leukemiaImmunologyMolecular responseNilotinibPegylated interferon-alfa2bQuality of life

Identifiers

PMID37119314
OpenAlexW4367368522

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.